Skip to main content
SpringerLink
Log in

Angiogenesis: A Therapeutic Target for Cancer

  • Chapter
  • First Online:
Drug Targets in Cellular Processes of Cancer: From Nonclinical to Preclinical Models

Abstract

The proliferation and metastatic spread of tumor cells depend on the newly developed blood vessels. Vasculature not only provides an adequate supply of oxygen and nutrients but also removes waste products or gas exchange. The process of angiogenesis is controlled by various transcriptional factors and growth factors. It has been observed that the discovery of angiogenic inhibitors can help to reduce carcinomas growth. Presently, chemotherapeutic drugs mediated inhibition of hypoxia-inducible factor (HIF-1), which initiates neovascularization under hypoxic conditions in the tumor, is being investigated. Vascular endothelial growth factor (VEGF) and receptor VEGFR mediated activation of endothelial cells are also inhibited by chemotherapeutic drugs. Furthermore, chemotherapeutic drugs inhibit the PI3K/AKT/mTOR signaling pathways mediated growth of new blood vessels. The aim of this chapter would be to highlight the role of angiogenesis in cancer progression. Furthermore, various anti-cancer therapeutic strategies/trials based upon inhibition of blood vessels would also be discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Lugano R, Ramachandran M, Dimberg A (2020) Tumor angiogenesis: causes, consequences, challenges and opportunities. Cell Mol Life Sci 77:1745–1770

    Article  CAS  PubMed  Google Scholar 

  2. Rajabi M, Mousa SA (2017) The role of angiogenesis in cancer treatment. Biomedicine 5(2):34

    Google Scholar 

  3. Folkman J (1971) Tumor angiogenesis. Therapeutic implications. N Engl J Med 285:1182–1186

    Article  CAS  PubMed  Google Scholar 

  4. Nishida N, Yano H, Nishida T, Kamura T, Kojiro M (2006) Angiogenesis in cancer. Vasc Health Risk Manag 2(3):213–219

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407:249–257

    Article  CAS  PubMed  Google Scholar 

  6. Folkman J, Kalluri R (2004) Cancer with disease. Nature 427:787

    Article  CAS  PubMed  Google Scholar 

  7. Park SA, Jeong MS, Ha KT, Jang SB (2018) Structure and function of vascular endothelial growth factor and its receptor system. BMB Rep 51(2):73–78

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Itatani Y, Kawada K, Yamamoto T, Sakai Y (2018) Molecular sciences resistance to anti-angiogenic therapy in cancer-alterations to anti-VEGF pathway. Int J Mol Sci 19:1232

    Article  PubMed Central  CAS  Google Scholar 

  9. Johnson KE, Wilgus TA (2014) Vascular endothelial growth factor and angiogenesis in the regulation of cutaneous wound repair. Adv Wound Care 3(10):647–661

    Article  Google Scholar 

  10. Rao N, Lee YF, Ge R (2015) Novel endogenous angiogenesis inhibitors and their therapeutic potential. Acta Pharmacol Sin 36(10):1177–1190

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Cohen MH, Gootenberg J, Keegan P, Pazdur R (2007) FDA drug approval summary: Bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer. Oncologist 12(3):356–361

    Article  CAS  PubMed  Google Scholar 

  12. Ucuzian AA, Gassman AA, East AT, Greisler HP (2010) Molecular mediators of angiogenesis. J Burn Care Res 31(1):158–175

    Article  PubMed  Google Scholar 

  13. Ward JP (2008) Oxygen sensors in context. Biochim Biophys Acta 1777:1–14

    Article  CAS  PubMed  Google Scholar 

  14. Semenza GL (2003) Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3:721–732

    Article  CAS  PubMed  Google Scholar 

  15. Pavlakovic H, Havers W, Schweigerer L (2001) Multiple angiogenesis stimulators in a single malignancy: implications for anti-angiogenic tumour therapy. Angiogenesis 4(4):259–262. https://doi.org/10.1023/a:1016045012466

    Article  CAS  PubMed  Google Scholar 

  16. Gerber HP, McMurtrey A, Kowalski J (1998) Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 273:30336

    Article  CAS  PubMed  Google Scholar 

  17. Park JE, Keller GA, Ferrara N (1993) The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol Biol Cell 4:1317

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Sarabipour S, Gabhann FM (2018) VEGF-A121a binding to neuropilins – a concept revisited. Cell Adhes Migr 12(3):204–214

    Article  CAS  Google Scholar 

  19. Karar J, Maity A (2011) PI3K/AKT/mTOR pathway in angiogenesis. Front Mol Neurosci 4:51

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Wang Z, Ahmad A, Li Y, Kong D, Azmi AS, Banerjee S, Sarkar FH (2010) Emerging roles of PDGF-D signaling pathway in tumor development and progression. Biochim Biophys Acta 1806(1):122–130

    CAS  PubMed  PubMed Central  Google Scholar 

  21. Fredriksson L, Hong L, Eriksson U (2004) The PDGF family: four gene products form five dimeric isoforms. Cytokine Growth Factor Rev 15:197–204

    Article  CAS  PubMed  Google Scholar 

  22. Laschke MW, Elitzsch A, Vollmer B, Vajkoczy P, Menger MD (2006) Combined inhibition of vascular endothelial growth factor (VEGF), fibroblast growth factor and platelet-derived growth factor, but not inhibition of VEGF alone, effectively suppress angiogenesis and vessel maturation in endometriotic lesions. Hum Reprod 21:262–268

    Article  CAS  PubMed  Google Scholar 

  23. Magnusson PU, Looman C, Ahgren A, Wu Y, Claesson-Welsh L, Heuchel RL (2007) Platelet-derived growth factor receptor-beta constitutive activity promotes angiogenesis in vivo and in vitro. Arterioscler Thromb Vasc Biol 27:2142–2149

    Article  CAS  PubMed  Google Scholar 

  24. Lo IC, Lin TM, Chou LH, Liu SL, Wu LW, Shi GY, Wu HL, Jiang MJ (2009) Ets-1 mediates platelet-derived growth factor-BB-induced thrombomodulin expression in human vascular smooth muscle cells. Cardiovasc Res 91:771–779

    Article  CAS  Google Scholar 

  25. Zhang J, Zhang H, Chen Y, Fu J, Lei Y, Sun J, Tang B (2019) Platelet-derived growth factor D promotes the angiogenic capacity of endothelial progenitor cells. Mol Med Rep 19(1):125–132

    CAS  PubMed  Google Scholar 

  26. Beenken A, Mohammadi M (2009) The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov 8:235–253

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Cao Y, Cao R, Hedlund EM (2008) R regulation of tumor angiogenesis and metastasis by FGF and PDGF signaling pathways. J Mol Med (Berl) 86:785–789

    Article  CAS  Google Scholar 

  28. Prager GW, Poettler M, Unseld M, Zielinski CC (2012) Angiogenesis in cancer: anti-VEGF escape mechanisms. Transl Lung Cancer Res 1(1):14–25

    PubMed  PubMed Central  Google Scholar 

  29. Hu B, Cheng SY (2009) Angiopoietin-2: development of inhibitors for cancer therapy. Curr Oncol Rep 11:111–116

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Ranieri G, Patruno R, Ruggieri E, Montemurro S, Paolo P, Ribatti D (2006) Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic. Curr Med Chem 13(16):1845–1857

    Article  CAS  PubMed  Google Scholar 

  31. Osanto S, van der Hulle T (2018) Cabozantinib in the treatment of advanced renal cell carcinoma in adults following prior vascular endothelial growth factor targeted therapy: clinical trial evidence and experience. Ther Adv Urol 10(3):109–123

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Yakes FM, Chen J, Tan J, Yamaguchi K, Shi Y, Yu P, Qian F, Chu F, Bentzien F, Cancilla B, Orf J, You A, Laird AD, Engst S, Lee L, Lesch J, Chou YC, Joly AH (2011) Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther 10(12):2298–2308

    Article  CAS  PubMed  Google Scholar 

  33. Kelly RJ, Rixe O (2009) Axitinib--a selective inhibitor of the vascular endothelial growth factor (VEGF) receptor. Target Oncol 4(4):297–305

    Article  PubMed  Google Scholar 

  34. Capozzi M, De Divitiis C, Ottaiano A, von Arx C, Scala S, Tatangelo F, Delrio P, Tafuto S (2019) Lenvatinib, a molecule with versatile application: from preclinical evidence to future development in anti-cancer treatment. Cancer Manag Res 11:3847–3860

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Shimodaira Y, Elimova E, Wadhwa R, Shiozaki H, Charalampakis N, Planjery V, Rogers JE, Song S, Ajani JA (2015) Ramucirumab for the treatment of gastroesophageal cancers. Expert Opin Orphan Drugs 3(6):737–746

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Goel G (2018) Evolution of regorafenib from bench to bedside in colorectal cancer: is it an attractive option or merely a “me too” drug? Cancer Manag Res 10:425–437

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Kim S, Yazici YD, Calzada G, Wang ZY, Younes MN, Jasser SA, Naggar AK, Myers JN (2007) Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. Mol Cancer Ther 6(6):1785–1792

    Article  CAS  PubMed  Google Scholar 

  38. Hao Z, Sadek I (2016) Sunitinib: the Antiangiogenic effects and beyond. Onco Targets Ther 9:5495–5505

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Patel A, Sun W (2014) Ziv-aflibercept in metastatic colorectal cancer. Biologics 8:13–25

    CAS  PubMed  Google Scholar 

  40. Chu M, Zhang C (2018) Inhibition of angiogenesis by leflunomide via targeting the soluble ephrin-A1/EphA2 system in bladder cancer. Sci Rep 8:1539

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  41. Wang Y, Kuramitsu Y, Baron B, Kitagawa T, Tokuda K, Akada J, Maehara S, Maehara Y, Nakamura K (2017) PI3K inhibitor LY294002, as opposed to wortmannin, enhances AKT phosphorylation in gemcitabine-resistant pancreatic cancer cells. Int J Oncol 50(2):606–612

    Article  CAS  PubMed  Google Scholar 

  42. Levy B, Spira A, Becker D, Evans T, Schnadig I, Camidge DR (2014) A randomized, phase 2 trial of Docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic non-small-cell lung cancer. J Thorac Oncol 9(7):1031–1035

    Article  CAS  PubMed  Google Scholar 

  43. Hashemzadeh K, Jokar MH, Sedighi S, Moradzadeh M (2019) Therapeutic potency of PI3K pharmacological inhibitors of gastrointestinal cancer. Middle East J Dig Dis 11(1):5–16

    Article  PubMed  Google Scholar 

  44. Schöffski P, Cresta S, Mayer IA (2018) A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer. Breast Cancer Res 20:109

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  45. Zumsteg ZS, Morse N, Krigsfeld G, Gupta G, Higginson DS, Lee NY, Morris L, Ganly I, Shiao SL, Powell SN, Chung CH, Scaltriti M, Baselga B (2016) Taselisib (GDC-0032), a potent β-sparing small molecule inhibitor of PI3K, radiosensitizes head and neck squamous carcinomas containing activating PIK3CA alterations. Clin Cancer Res 22(8):2009–2019

    Article  CAS  PubMed  Google Scholar 

  46. Nair KS, Cheson B (2016) The role of idelalisib in the treatment of relapsed and refractory chronic lymphocytic leukemia. Ther Adv Hematol 7(2):69–84

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Kondapaka SB, Singh SS, Dasmahapatra GP, Sausville EA, Roy KK (2003) Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol Cancer Ther 2(11):1093–1103

    CAS  PubMed  Google Scholar 

  48. Rhodes N, Heerding DA, Duckett DR, Eberwein DJ, Knick VB, Lansing TJ (2008) Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity. Cancer Res 68(7):2366–2374

    Article  CAS  PubMed  Google Scholar 

  49. Yin Y, Hua H, Li M, Liu S, Kong Q, Shao T (2016) mTORC2 promotes type I insulin-like growth factor receptor and insulin receptor activation through the tyrosine kinase activity of mTOR. Cell Res 26:46–65

    Article  CAS  PubMed  Google Scholar 

  50. Wong SW, Tiong KH, Kong WY, Yue YC, Chua CH, Lim JY (2011) Rapamycin synergizes cisplatin sensitivity in basal-like breast cancer cells through up-regulation of p73. Breast Cancer Res Treat 128:301–313

    Article  CAS  PubMed  Google Scholar 

  51. Malizzia LJ, Hsu A (2008) Temsirolimus, an mTOR inhibitor for treatment of patients with advanced renal cell carcinoma. Clin J Oncol Nurs 12(4):639–646

    Article  PubMed  Google Scholar 

  52. Rizzieri DA, Feldman E, DiPersio JF, Gabrail N, Stock W, Strair R, Rivera VM, Albitar M, Bedrosian CL, Giles FJ (2008) A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 14(9):2756–2762

    Article  CAS  PubMed  Google Scholar 

  53. Graupera M, Guillermet-Guibert J, Foukas LC, Li-Kun Phng, Cain RJ, Salpekar A, Pearce W, Meek S, Millan J, Cutillas PR, Smith AJH, Ridley AJ, Ruhrberg C, Gerhardt H, Vanhaesebroeck B (2008), Angiogenesis selectively requires the p110alpha isoform of PI3K to control endothelial cell migration, Nature, 453(7195):662–6

    Google Scholar 

  54. Yao C, Wei JJ, Wang ZY, Ding HM, Li D, Yan SC (2013) Perifosine induces cell apoptosis in human osteosarcoma cells: new implication for osteosarcoma therapy? Cell Biochem Biophys 65(2):217–227

    Article  CAS  PubMed  Google Scholar 

  55. Engel JB, Schönhals T, Häusler S, Krockenberger M, Schmidt M, Horn E (2011) Induction of programmed cell death by inhibition of AKT with the alkylphosphocholine perifosine in in vitro models of platinum sensitive and resistant ovarian cancers. Arch Gynecol Obstet 283(3):603–610. https://doi.org/10.1007/s00404-010-1457-6

    Article  CAS  PubMed  Google Scholar 

  56. Guertin DA, Sabatini DM (2009) The pharmacology of mTOR inhibition. Sci Signal 2(67):24

    Article  Google Scholar 

  57. Niessner H, Kosnopfel C, Sinnberg T, Beck D, Krieg K, Wanke I, Lasithiotakis K, Bonin M, Garbe C, Meier F (2017) Combined activity of temozolomide and the mTOR inhibitor temsirolimus in metastatic melanoma involves DKK1. Exp Dermatol 26(7):598–606

    Article  CAS  PubMed  Google Scholar 

  58. Rangwala R, Chang C, Hu J, Algazy K, Evans T, Fecher L, Schuchter L, Torigian DA, Panossian J, Troxel T (2014) Combined MTOR and autophagy inhibition: phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma. Autophagy 10(8):1391–1402

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Rapisarda A, Uranchimeg B, Scudiero DA (2002) Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res 62(15):4316–4324

    CAS  PubMed  Google Scholar 

  60. Chang H, Shyu KG, Lee CC (2003) GL331 inhibits HIF-1α expression in a lung cancer model. Biochem Biophys Res Commun 302:95–100

    Article  CAS  PubMed  Google Scholar 

  61. Zhang C, Yang C, Feldman M, Wang H, Pang Y, Maggio DM, Zhu D, Nesvick CL, Dmitriev P, Bullova P, Chittiboina P, Brady R, Pacak K, Zhuang Z (2017) Vorinostat suppresses hypoxia signaling by modulating nuclear translocation of hypoxia inducible factor 1 alpha. Oncotarget 8(34):56110–56125

    Article  PubMed  PubMed Central  Google Scholar 

  62. Yang CY, Chen C, Lin CY, Chen YH, Lin CY, Chi CW, Chen YJ, Liu SC, Chang TK, Tang CH, Lai YW, Tsai HJ, Chen JJ, Wang SW (2019) Garcimultiflorone K inhibits angiogenesis through Akt/eNOS- and mTOR-dependent pathways in human endothelial progenitor cells. Phytomedicine 64:152911

    Article  CAS  PubMed  Google Scholar 

  63. Kashyap AS, Schmittnaegel M, Rigamonti N, Ferreira DP, Mueller P, Buchi M, Ooi CH, Kreuzaler M, Hirschmann P, Guichard A, Rieder N, Bill R, Herting F, Kienast Y, Dirnhofer S, Klein C, Hoves S, Ries CH, Corse Palma MD, Zippelius A (2020) Optimized antiangiogenic reprogramming of the tumor microenvironment potentiates CD40 immunotherapy. Proc Natl Acad Sci U S A 117(1):541–551

    Article  CAS  PubMed  Google Scholar 

  64. Ramirez JS, Bequet-Romero M, Diaz YM, Hernandez-Bernal F, Avila MA (2019) Does VEGF-targeted active immunotherapy induce complete abrogation of platelet VEGF levels? BMC Res Notes 12:323

    Article  CAS  Google Scholar 

  65. Li J, Hao Q, Cao W, Vadgama JV, Wu Y (2018) Celecoxib in breast cancer prevention and therapy. Cancer Manag Res 10:4653–4667

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Toloczko-Iwaniuk N, Dziemiańczyk-Pakieła D, Nowaszewska BK, Celińska-Janowicz K, Miltyk W (2019) Celecoxib in cancer therapy and prevention-review. Curr Drug Targets 20:302–315

    Article  CAS  PubMed  Google Scholar 

  67. Andrews P, Zhao X, Allen J, Li F, Chang M (2008) A comparison of the effectiveness of selected non-steroidal anti-inflammatory drugs and their derivatives against cancer cells in vitro. Cancer Chemother Pharmacol 61:203–214

    Article  CAS  PubMed  Google Scholar 

  68. Sleire L, Førde HE, Netland IA, Leiss L, Skeie BS, Enger PØ (2017) Drug repurposing in cancer. Pharmacol Res 124:74–91

    Article  CAS  PubMed  Google Scholar 

  69. Zhao Y, Wang W, Guo S, Wang Y, Miao L, Xiong Y, Huang L (2016) PolyMetformin combines carrier and anticancer activities for in vivo siRNA delivery. Nat Commun 7:11822

    Article  PubMed  PubMed Central  Google Scholar 

  70. Clavreul A, Roger E, Pourbaghi-Masouleh M, Lemaire L, Tétaud C, Menei P (2018) Development and characterization of sorafenib-loaded lipid nanocapsules for the treatment of glioblastoma. Drug Deliv 25:1756–1765

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Pal K, Madamsetty VS, Dutta SK, Mukhopadhyay D (2019) Co-delivery of everolimus and vinorelbine via a tumor-targeted liposomal formulation inhibits tumor growth and metastasis in RCC. Int J Nanomedicine 14:5109–5123

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Abud MB, Louzada RN, Isaac DLC, Souza LG, dos Reis RG, Lima EM, de Ávila MP (2019) In vivo and in vitro toxicity evaluation of liposome-encapsulated sirolimus. Int J Retin Vitr 5:35

    Article  Google Scholar 

  73. Satchi-Fainaro R, Puder M, Davies JW, Tran HT, Sampson DA, Greene AK, Corfas G, Folkman J (2004) Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470. Nat Med 10:255–261

    Article  CAS  PubMed  Google Scholar 

  74. Tian F, Dahmani FZ, Qiao J, Ni J, Xiong H, Liu T, Zhou J, Yao J (2018) A targeted nanoplatform co-delivering chemotherapeutic and antiangiogenic drugs as a tool to reverse multidrug resistance in breast cancer. Acta Biomater 75:398–412

    Article  CAS  PubMed  Google Scholar 

  75. Balakrishnan S, Bhat FA, Raja Singh P, Mukherjee S, Elumalai P, Das S, Patra CR, Arunakaran J (2016) Gold nanoparticle-conjugated quercetin inhibits epithelial-mesenchymal transition, angiogenesis and invasiveness via EGFR/VEGFR-2-mediated pathway in breast cancer. Cell Prolif 49:678–697

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. Giri S, Karakoti A, Graham RP, Maguire JL, Reilly CM, Seal S, Rattan R, Shridhar V (2013) Nanoceria: a rare-earth nanoparticle as a novel anti-angiogenic therapeutic agent in ovarian cancer. PLoS One 8:e54578

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Lin T, Zhao P, Jiang Y, Tang Y, Jin H, Pan Z, He H, Yang VC, Huang Y (2016) Blood–brain-barrier-penetrating albumin nanoparticles for biomimetic drug delivery via albumin-binding protein pathways for antiglioma therapy. ACS Nano 10:9999–10012

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Plexision Inc, Pittsburgh, PA, USA

    Neha Atale

  2. Jaypee Institute of Information Technology, Noida, Uttar Pradesh, India

    Vibha Rani

Authors
  1. Neha Atale
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vibha Rani
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Biotechnology, Maharishi Markandeshwar (Deemed to be University), Mullana, Ambala, Haryana, India

    Hardeep Singh Tuli

Rights and permissions

Reprints and permissions

Copyright information

© 2020 The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Atale, N., Rani, V. (2020). Angiogenesis: A Therapeutic Target for Cancer. In: Tuli, H.S. (eds) Drug Targets in Cellular Processes of Cancer: From Nonclinical to Preclinical Models. Springer, Singapore. https://doi.org/10.1007/978-981-15-7586-0_9

Download citation

Publish with us

Policies and ethics

Search

Navigation